Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report.

Palcu P, Dion N, Ste-Marie LG, Goltzman D, Radziunas I, Miller PD, Jamal SA.

Am J Kidney Dis. 2015 Jun;65(6):933-6. doi: 10.1053/j.ajkd.2015.01.025. Epub 2015 Apr 2.

PMID:
25843705
2.

Effect of teriparatide on early bone loss after kidney transplantation.

Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, Haas M.

Am J Transplant. 2008 Sep;8(9):1864-70. doi: 10.1111/j.1600-6143.2008.02327.x.

3.

Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study.

Cejka D, Kodras K, Bader T, Haas M.

Kidney Blood Press Res. 2010;33(3):221-6. doi: 10.1159/000316708. Epub 2010 Jun 24.

4.

[Teriparatide:benefit and safety for bone disease in CKD patients undergoing hemodialysis].

Yamamoto S, Ei I, Narita I.

Clin Calcium. 2016 Sep;26(9):1301-7. doi: CliCa160913011307. Japanese.

PMID:
27561345
5.

[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].

Lorenzo Sellares V, Torregrosa V.

Nefrologia. 2008;28 Suppl 3:67-78. Spanish.

6.

Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.

Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.

J Am Geriatr Soc. 2006 May;54(5):782-9.

PMID:
16696744
7.

Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study.

Mitsopoulos E, Ginikopoulou E, Economidou D, Zanos S, Pateinakis P, Minasidis E, Memmos D, Thodis E, Vargemezis V, Tsakiris D.

Am J Nephrol. 2012;36(3):238-44. Epub 2012 Aug 31.

PMID:
22948280
8.
9.

Relationship between bone mineral density and biochemical markers of bone turnover in hemodialysis patients.

Sit D, Kadiroglu AK, Kayabasi H, Atay AE, Yilmaz Z, Yilmaz ME.

Adv Ther. 2007 Sep-Oct;24(5):987-95.

PMID:
18029324
10.

Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report.

Fahrleitner-Pammer A, Wagner D, Krisper P, Amrein K, Dimai H.

Osteoporos Int. 2017 Mar;28(3):1149-1152. doi: 10.1007/s00198-016-3858-2. Epub 2016 Dec 17.

11.

Treatment of adult hypophosphatasia with teriparatide.

Camacho PM, Painter S, Kadanoff R.

Endocr Pract. 2008 Mar;14(2):204-8.

PMID:
18308659
12.

Reducing the risk of re-fracture in the dialysis population: is it time to consider therapy with PTH analogues?

Jamal SA, Hodsman AB.

Semin Dial. 2011 Jan-Feb;24(1):12-5. doi: 10.1111/j.1525-139X.2010.00817.x. Epub 2011 Feb 7.

PMID:
21299630
13.

PINP as an aid for monitoring patients treated with teriparatide.

Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH.

Bone. 2011 Apr 1;48(4):798-803. doi: 10.1016/j.bone.2010.12.006. Epub 2010 Dec 17.

PMID:
21168536
14.

Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.

Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.

J Assoc Physicians India. 2008 Jun;56:418-24.

PMID:
18822620
15.

A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study.

Kung AW, Pasion EG, Sofiyan M, Lau EM, Tay BK, Lam KS, Wilawan K, Ongphiphadhanakul B, Thiebaud D.

Curr Med Res Opin. 2006 May;22(5):929-37.

PMID:
16709314
16.

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.

Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.

Bone. 2006 Aug;39(2):237-43. Epub 2006 Mar 24.

PMID:
16563890
18.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75. Epub 2006 Aug 1.

PMID:
16884968
19.

ADULT HYPOPHOSPHATASIA TREATED WITH TERIPARATIDE: REPORT OF 2 PATIENTS AND REVIEW OF THE LITERATURE.

Camacho PM, Mazhari AM, Wilczynski C, Kadanoff R, Mumm S, Whyte MP.

Endocr Pract. 2016 Aug;22(8):941-50. doi: 10.4158/EP15890.OR. Epub 2016 Apr 4. Review.

PMID:
27042741
20.

Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma.

Arantes HP, Barros ER, Kunii I, Bilezikian JP, Lazaretti-Castro M.

J Bone Miner Res. 2011 Dec;26(12):2823-6. doi: 10.1002/jbmr.530.

Supplemental Content

Support Center